EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Extracellular Vesicles in Renal Fibrosis: Mechanisms, Biomarkers, and Nanotherapeutics in Chronic Kidney Disease

Tianyi Zhang, Qingyu Zhao, Shenyuan Chen, Wenrong Xu, Chenyan Zhang, Hui Qian, Jiajia Jiang

International Journal of Nanomedicine · 2026-11 · Volume 21 · 1-26

DOI: 10.2147/ijn.s654097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026-11. Verfasst von Tianyi Zhang und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal fibrosis contributes to the progression of chronic kidney disease (CKD), yet its assessment and treatment remain challenging. Extracellular vesicles (EVs) mediate intercellular communication and can promote or attenuate fibrotic remodeling by influencing renal-cell injury, immune responses, and extracellular matrix production. Their effects depend on donor-cell conditions, cargo composition, and recipient responses. Urinary and circulating EV profiles offer candidate diagnostic and prognostic biomarkers. Protective EV preparations have reduced fibrosis in experimental kidney disease models, while engineering strategies are being developed to improve therapeutic cargo loading and delivery to renal target cells. This narrative review integrates both profibrotic and antifibrotic EV mechanisms in CKD-associated renal fibrosis and systematically evaluates the translational evidence for EV-based diagnosis and treatment. It examines causal support for intercellular signaling and associations of candidate biomarkers with tissue fibrosis and renal outcomes. It also evaluates evidence of functional cargo delivery and antifibrotic efficacy. Clinical translation remains limited by challenges in EV standardization, biodistribution, reproducible manufacturing, and clinical validation. Extracellular vesicles and non-vesicular extracellular particles in renal fibrosis, showing particle size ranges, profibrotic and antifibrotic EV pathways, liquid biopsy biomarkers and engineered EV therapeutics. Top section lists extracellular particle types with sizes: Exosome, 30 to 150 nanometer. Migrasome, 0.5 to 3 micrometer. Microparticle, 100 to 1500 nanometer. Apoptotic body, 50 nanometer to 5 micrometer. Exopher, 3.5 to 4 micrometer. Large oncosome, 1 to 10 micrometer. Blebbisome, 5 to 20 micrometer. Supermere, 22 to 32 nanometer. Exomere, 28 to 50 nanometer. Vault, 40 by 70 nanometer. Lipoprotein, 5 to 80 nanometer. Middle section centers on the text, EVs in renal fibrosis, between two sides. Left side heading reads, EV-mediated profibrotic responses, with a kidney labeled, Fibrotic kidney. Right side heading reads, EV-mediated antifibrotic responses, with a kidney labeled, Reduced renal fibrosis. Labels around the center include: CHIP; miR-122-5p; IL-10; let-7b-5p; miR-99b-5p; TGF-beta slash Smad; HIF-1 alpha; Immune modulation; TGFBR1 ARID3a; mTOR Autophagy; TGF-beta; HHIP; MMP-7; VEGFA; DAMPs. Next section title reads, EVs as potential liquid biopsy biomarkers. Four groups are shown: TEC-EVs with miR-20a-5p and miR-21-5p. Podo-EVs with Podocalyxin, Podoplanin, Nephrin. Other uEVs with miR-150, miR-29c, miR-21. Circulating EVs with miR-192-5p, miR-21-5p, miR-146a-5p. Bottom section title reads, Engineering EV-based therapeutics for renal fibrosis. Methods and components shown include: Natural carriers; Electroporation; Chemical transfection; Freeze-thaw cycles; Extrusion; Click chemistry; Hydrophobic insertion; RGD peptide modification; DNA slash RNA aptamer; LAMP-2B-mediated display; Peptide; Nanobody. A left box lists: RVG peptide; RGD peptide; miR-23a; 27a; 26a; miR-218-5p. A right box lists: CP05 CD63; IL-10; CHIP; Integrin alpha v beta 3.Infographic summarizing extracellular vesicles in renal fibrosis, biomarkers and engineered EV therapeutics.

Zitieren

APA

Zhang, T., Zhao, Q., Chen, S., Xu, W., Zhang, C., Qian, H., & Jiang, J. (2026). Extracellular Vesicles in Renal Fibrosis: Mechanisms, Biomarkers, and Nanotherapeutics in Chronic Kidney Disease. International Journal of Nanomedicine, Volume 21, 1-26. https://doi.org/10.2147/ijn.s654097

Vancouver

Zhang T, Zhao Q, Chen S, Xu W, Zhang C, Qian H, et al. Extracellular Vesicles in Renal Fibrosis: Mechanisms, Biomarkers, and Nanotherapeutics in Chronic Kidney Disease. International Journal of Nanomedicine. 2026;Volume 21:1-26. doi:10.2147/ijn.s654097

BibTeX
@article{Zhang2026,
  author = {Zhang, Tianyi and Zhao, Qingyu and Chen, Shenyuan and Xu, Wenrong and Zhang, Chenyan and Qian, Hui and Jiang, Jiajia},
  title = {Extracellular Vesicles in Renal Fibrosis: Mechanisms, Biomarkers, and Nanotherapeutics in Chronic Kidney Disease},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  volume = {Volume 21},
  pages = {1--26},
  doi = {10.2147/ijn.s654097}
}
Kostenlos starten →